drugset / Trial / NCT06755684
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
Timeline
- Start
- 2024-11-07
- Primary completion
- 2025-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Background | Befotertinib | Small molecule | — | — |